A Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study to of oral NMD1343 in healthy male and female volunteers
Latest Information Update: 25 May 2023
At a glance
- Drugs NMD 1343 (Primary)
- Indications Neuromuscular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors NMD Pharma
Most Recent Events
- 25 May 2023 New trial record
- 23 May 2023 According to a NMD Pharma media release, the study was reviewed and approved by the Medicines & Healthcare products Regulatory Agency (MHRA).
- 23 May 2023 According to a NMD Pharma media release, the first healthy volunteers have been dosed at the study site in London, UK.